Median Overall Survival

Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer
Nitya Nair, Ed Lemmens, Amanda Enstrom, Shih-Yu Chen, Serena Chang, Dung Le, Elizabeth M Jaffee, Holden Maecker, Aimee L Murphy, Dirk G Brockstedt, Chan Whiting

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P102; DOI: 10.1186/2051-1426-3-S2-P102
Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
Réjean Lapointe, Rahima Jamal, Leon van Kempen, Pamela Thebault, Karl Belanger, Jennifer Friedmann, Jean-Pierre Ayoub, Eftihia Cocolakis, Shirin Kazemi, Jeanne Dionne, Caroline Lambert, Huy Le, Cecile Grange, Jean-Francois Cailhier, Alan Spatz, Wilson Miller

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P259; DOI: 10.1186/2051-1426-3-S2-P259
Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
David B Page, Jarushka Naidoo, Parisa Momtaz, Kita Bogatch, Deborah Kuk, Katherine Panageas, Jianda Yuan, Jedd D Wolchok, Michael Postow

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P117; DOI: 10.1186/2051-1426-2-S3-P117
Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
Howard L Kaufman, Robert HI Andtbacka, Frances A Collichio, Michael Wolf, Ai Li, Mark Shilkrut, Igor Puzanov, Merrick Ross

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P91; DOI: 10.1186/2051-1426-2-S3-P91
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
Shien Chow, Manon Evans, Victoria Galvis, Rebecca Leach, Elizabeth Keene, Kevin Chan, Andrea Spencer-Shaw, Shanks Jonathan, Alaaeldin Shabalak, Fiona Thistlethwaite, Robert Hawkins

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P89; DOI: 10.1186/2051-1426-2-S3-P89
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase
Trine Z Iversen, Lotte Engell-Noerregaard, Eva Ellebaek, Rikke Andersen, Stine K Larsen, Jon Bjoern, Claus Zeyher, Cécile Gouttefangeas, Birte M Thomsen, Bente Holm, Per thor Straten, Anders Mellemgaard, Mads H Andersen, Inge M Svane

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P273; DOI: 10.1186/2051-1426-1-S1-P273
The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
Antonio M Grimaldi, Ester Simeone, Diana Giannarelli, Marco Palla, Paolo Muto, Sara Falivene, Fabio Sandomenico, Antonella Petrillo, Marcello Curvietto, Assunta Esposito, Miriam Paone, Corrado Caracò, Gennaro Ciliberto, Nicola Mozzillo, Paolo A Ascierto

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) O23; DOI: 10.1186/2051-1426-1-S1-O23
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Paolo Antonio Ascierto, E Simeone, V Chiarion Sileni, P Queirolo, M Del Vecchio, L Di Guardo, M Guidoboni, P Marchetti, GC Antonini Cappellini, PF Ferrucci, F Cognetti, MG Bernengo, M Guida, R Marconcini, M Mandalà, C Cimminiello, G Rinaldi, M Aglietta, L Calabrò, M Maio

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P69; DOI: 10.1186/2051-1426-1-S1-P69
Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab
Jianda Yuan, Jun Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S Panageas, Philip Wong, Jedd D Wolchok, F Stephen Hodi

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P247; DOI: 10.1186/2051-1426-1-S1-P247

Log in using your username and password

Main menu

Log in using your username and password

You are here

Median Overall Survival